Thrombosis Research

• 

  Publication Venue For

  • The progression from coagulopathy to disseminated intravascular coagulation in representative underlying diseases..  179:11-14. 2019
  • Protection of the endothelial glycocalyx by antithrombin in an endotoxin-induced rat model of sepsis..  171:1-6. 2018
  • International, multicenter evaluation of a new D-dimer assay for the exclusion of venous thromboembolism using standard and age-adjusted cut-offs..  166:63-70. 2018
  • Variants in chondroitin sulfate metabolism genes in thrombotic storm..  161:43-51. 2018
  • PF4-HIT antibody (KKO) complexes activate broad innate immune and inflammatory responses..  159:39-47. 2017
  • Management of hereditary antithrombin deficiency in pregnancy..  157:41-45. 2017
  • Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial..  156:184-190. 2017
  • Feasibility of the Von Willebrand disease PREVENT trial..  156:8-13. 2017
  • Generation and characterization of aptamers targeting factor XIa..  156:134-141. 2017
  • Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin..  146:113-118. 2016
  • Recognizing the risk of postpartum thrombosis among obese women and planning accordingly..  145:157-158. 2016
  • Low molecular weight heparin to prevent postpartum venous thromboembolism: A pilot study to assess the feasibility of a randomized, open-label trial..  142:17-20. 2016
  • Inter-observer reliability of the HERDOO2 clinical decision rule..  141:136-138. 2016
  • Systematic review of anticoagulant treatment of catheter-related thrombosis..  136:1103-1109. 2015
  • Characteristics and Risk Factors of Cancer Associated Venous Thromboembolism..  136:535-541. 2015
  • Whole blood gene expression profiles distinguish clinical phenotypes of venous thromboembolism.  135:659-665. 2015
  • Whole blood gene expression profiles distinguish clinical phenotypes of venous thromboembolism..  135:659-665. 2015
  • Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees..  135:50-57. 2015
  • Characterization of antithrombin levels in pregnancy..  134:648-651. 2014
  • A mouse bleeding model to study oral anticoagulants..  133 Suppl 1:S6-S8. 2014
  • Guidelines for treatment and prevention of venous thromboembolism among patients with cancer.  133:S122-S127. 2014
  • Hemostasis: old system, new players, new directions..  133 Suppl 1:S1-S2. 2014
  • Thromboprophylaxis with fondaparinux in high-risk postoperative patients with renal insufficiency..  133:629-633. 2014
  • Differences in thrombotic risk factors in black and white women with adverse pregnancy outcome.  133:108-111. 2014
  • Differences in thrombotic risk factors in black and white women with adverse pregnancy outcome..  133:108-111. 2014
  • Thromboprophylaxis with fondaparinux in high-risk postoperative patients with renal insufficiency.  133:629-633. 2014
  • Postpartum wound and bleeding complications in women who received peripartum anticoagulation..  132:e19-e23. 2013
  • In vitro effects of recombinant activated factor VII on thrombin generation and coagulation following inhibition of platelet procoagulant activity by prasugrel.  132:106-111. 2013
  • Postpartum wound and bleeding complications in women who received peripartum anticoagulation.  132:e19-e23. 2013
  • Characterization of the hypercoagulable state in patients with sickle cell disease..  130:e241-e245. 2012
  • The procoagulant properties of purified fibrinogen concentrate are enhanced by carbon monoxide releasing molecule-2..  129:793-796. 2012
  • Lack of association between serum paraoxonase-1 activity and residual platelet aggregation during dual anti-platelet therapy..  129:e36-e40. 2012
  • Obesity-related Coagulation Changes in Pregnancy.  129:204-206. 2012
  • Hemostatic properties of the FVIIa analog NN1731.  129:S49-S50. 2012
  • Time dependence of clopidogrel loading effect: platelet activation versus platelet aggregation..  129:1-2. 2012
  • Whole blood gene expression analyses in patients with single versus recurrent venous thromboembolism..  128:536-540. 2011
  • Elevated factor VIII enhances thrombin generation in the presence of factor VIII-deficiency, factor XI-deficiency or fondaparinux..  127:135-140. 2011
  • Prevention and treatment of venous thromboembolism among patients with cancer: the American Society of Clinical Oncology Guidelines..  125 Suppl 2:S120-S127. 2010
  • A time-tested ex vivo model of thrombosis: From pathophysiology to drug development and disease application.  126:363-364. 2010
  • Anti-factor IXa Aptamer reduces propagation of thrombin generation in plasma anticoagulated with warfarin.  125:432-437. 2010
  • Diagnosis and management of inherited von Willebrand disease in the next decade: panel discussion..  124 Suppl 1:S20-S21. 2009
  • Biological and pharmacological aspects of perioperative hemorrhagic complications associated with oral platelet-directed antithrombotic agents. Focus on isolated coronary artery bypass grafting and oral irreversible P2Y(12) receptor antagonists..  123:419-428. 2009
  • Association between thrombosis and bloodstream infection in neonates with peripherally inserted catheters..  122:782-785. 2008
  • Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation.  122:117-123. 2008
  • Platelet activation and its patient-specific consequences.  122:435-441. 2008
  • Some things I thought I knew about tissue factor that turn out to be wrong..  122 Suppl 1:S73-S77. 2008
  • Thrombophilia screening in asymptomatic children..  121:597-604. 2008
  • Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients..  121:107-115. 2007
  • Atherothrombosis at a distance: contributing role of existing large-burden vascular disease, circulating biosignals and modulating extravascular tissues..  119:761-768. 2007
  • Clopidogrel resistance?.  120:311-321. 2007
  • Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting..  119:563-570. 2007
  • Pro-thrombotic and pro-oxidant effects of diet-induced hyperhomocysteinemia..  120:117-126. 2007
  • Hemostatic activation in a chemically induced rat model of severe hemolysis and thrombosis..  118:747-753. 2006
  • Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease..  117:439-446. 2006
  • Thrombosis Research: Preface.  117:1-3. 2005
  • Clinical implications for patients on antithrombotic therapy while taking supplements..  117:75-80. 2005
  • Dialogue with patient care organizations..  117:211-222. 2005
  • The difference between clopidogrel responsiveness and posttreatment platelet reactivity..  115:89-94. 2005
  • Clopidogrel does not induce fibrinolysis in healthy subjects..  114:97-100. 2004
  • The stratification of platelet reactivity and activation in patients with stable coronary artery disease on aspirin therapy..  112:9-12. 2003
  • Heparin prevents xylum clot signature analyser to detect platelet inhibition with clopidogrel during coronary stenting [2].  102:95-97. 2001
  • Clinical utility of the platelet function analyzer (PFA-100) for the assessment of the platelet status in patients with congestive heart failure (EPCOT trial)..  101:427-433. 2001
  • Platelet function and total length of intracoronary stents: is there a correlation?.  101:105-107. 2001
  • Initial platelet activity may predict efficacy after chronic oral glycoprotein IIb/IIIa blockade: should we still consider uniform treatment regimens?.  99:105-107. 2000
  • The flow cytometer model markedly affects measurement of ex vivo whole blood platelet-bound P-selectin expression in patients with chest pain: are we comparing apples with oranges..  96:51-56. 1999
  • Storing paraformaldehyde-fixed whole blood patient samples after chronic platelet glycoprotein IIb/IIIa blockade: core laboratory considerations..  95:201-203. 1999
  • Moderate hyperhomocyst(e)inemia is associated with the presence of coronary artery disease and the severity of coronary atherosclerosis in Koreans..  94:45-52. 1999
  • Assessment of platelet activity by measuring platelet-derived substances in plasma from patients with acute myocardial infarction: surprising lessons from the GUSTO-III Platelet Study..  93:149-150. 1999
  • S-nitrosoglutathione/glutathione disulphide/Cu2+-dependent stimulation of L-arginine transport in human platelets..  91:113-120. 1998
  • Myths and realities of P-selectin plasma levels in patients with acute myocardial infarction..  88:343-344. 1997
  • Variability in platelet procoagulant activity in healthy volunteers..  81:533-543. 1996
  • An animal model of fibrinolytic bleeding based on the rebleed phenomenon: application to a study of vulnerability of hemostatic plugs of different age..  67:31-40. 1992
  • Effects of 9, 12, 15-octadecatrien-6-ynoic acid on the metabolism of arachidonic acid in platelets and on platelet aggregation..  65:687-698. 1992
  • Recombinant hirudin displaces human factor Xa from its endothelial binding sites..  57:803-806. 1990
  • Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator..  57:155-162. 1990
  • Production of chemotactic peptides by neutrophil degradation of heparin cofactor II..  57:77-85. 1990
  • Human mononuclear phagocyte transglutaminase activity cross-links fibrin..  55:57-68. 1989
  • The effect of phosphatidylserine on the inhibition of human factor Xa by the plasma proteinase inhibitors..  50:901-906. 1988
  • EVIDENCE FOR THE INVOLVEMENT OF PLATELET GLYCOPROTEINS OTHER THAN GP-IB IN HEPARIN-ASSOCIATED THROMBOCYTOPENIA AND THROMBOSIS.  45:421-425. 1987
  • The macrophage-mediated regulation of hepatocyte synthesis of antithrombin III and alpha 1-proteinase inhibitor..  41:707-715. 1986
  • Precipitation of fibrinogen, fibrinogen degradation products and fibrin monomer by histone H3..  39:97-116. 1985
  • In vitro effects of acetaminophen and its analogues on human platelet aggregation and thromboxane B2 synthesis..  38:33-43. 1985
  • Inhibitory effect of ristocetin and factor VIII/von Willebrand factor protein on human platelet adenylate cyclase activity..  30:301-308. 1983
  • Lack of thromboxane A2 synthesis in platelet aggregation induced by factor VIII/von Willebrand factor..  24:245-251. 1981
  • The bleeding diathesis in human glycogen storage disease type I: in vitro identification of a naturally occurring inhibitor of ristocetin-induced platelet aggregation..  18:683-692. 1980
  • Effectiveness of intermittent pulsatile elastic stockings for the prevention of calf and thigh vein thrombosis in patients undergoing elective knee surgery..  16:37-45. 1979
  • Streptokinase-induced degradation of crosslinked and uncrosslinked clots..  13:569-575. 1978
  • Catabolism of antithrombin III-protease complexes..  32:253-254. 1983
  • Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. 2017
  • Von Willebrand disease in women: awareness and diagnosis 2009
  • Guidelines for bleeding disorders in women 2009
  • Management of valvular heart disease in pregnancy 2007
  • More than menorrhagia: A review of the obstetric and gynaecological manifestations of von Willebrand disease 2007